Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing email@example.com or calling +44 (0)1707 367554.
Assessing bleed management and quality of life with haemophilia A prophylaxis
At the International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress, leading experts on haemophilia A came together to discuss recent advances, the latest science and real-world applications designed to improve patient care.
ISTH 2021 Congress poster presentations from or supported by Roche/Chugai
Links to Roche/Chugai sponsored posters from the ISTH Congress, held 19 July 2021.
521 Final analysis of the STASEY trial: a single-arm, multicenter, open-label, Phase III clinical trial evaluating the safety and tolerability of emicizumab prophylaxis in persons with haemophilia A with factor (F)VIII inhibitors
Jiménez-Yuste V et al.
Video highlights from the Roche-Sponsored Virtual Symposium
Consultant Haematologist, Dr Jecko Thachil, discusses therapeutic approaches used to target the ‘zero bleeds milestone.’ Using clinical evidence, Dr Thachil evaluates two strategies for patients with haemophilia A: managing FVIII trough levels and sustaining plasma concentrations.
Based on insights from his clinical practice, Dr Thachil describes the challenges of managing physically active adults with haemophilia A. He presents a case study to illustrate how HEMLIBRA is helping his patients achieve their activity goals.
Dr Jecko Thachil, Consultant Haematologist, Manchester Royal Infirmary
Dr Thachil is a consultant in haemostasis and thrombosis at the Manchester Royal Infirmary, as well as an honorary senior lecturer at the Liverpool School of Tropical Medicine. His work on bleeding disorders is based in one of the largest haemophilia treatment centres in the UK. Previously, his research focused on the role of platelet interaction with white blood cells in inflammation and sepsis. Currently, Dr Thachil is researching new therapies in haemophilia, anticoagulation in kidney disease and expanding his speciality in low- and middle-income countries.
Internationally, Dr Thachil has served as the chairman of the Disseminated Intravascular Coagulation (DIC) subcommittee of the ISTH and was identified to be among the top three healthcare professionals in the world in this area (Expertscape). He has published over 300 peer-reviewed papers, and edited and written chapters for books, including Haematology in critical care and Handbook of venous thromboembolism.
DIC, Disseminated Intravascular Coagulation; FVIII, Factor VIII; ISTH, International Society on Thrombosis and Haemostasis.
- HEMLIBRA Summary of Product Characteristics.
Date of preparation: August 2021